130 related articles for article (PubMed ID: 9523729)
1. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors.
Yan Z; Zhu ZL; Qian ZZ; Hu G; Wang HQ; Liu WH; Cheng G
Acta Pharmacol Sin; 2012 Jun; 33(6):852-8. PubMed ID: 22669119
[TBL] [Abstract][Full Text] [Related]
4. Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates.
Shah NN; Cole DE; Lester-McCully CM; Wayne AS; Warren KE; Widemann BC
Invest New Drugs; 2016 Feb; 34(1):61-5. PubMed ID: 26661090
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
Silverman JA; Reynolds L; Deitcher SR
J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
[TBL] [Abstract][Full Text] [Related]
6. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection.
Embree L; Gelmon KA; Tolcher AW; Hudon NJ; Heggie JR; Dedhar C; Webb MS; Bally MB; Mayer LD
J Pharm Biomed Anal; 1997 Dec; 16(4):675-87. PubMed ID: 9502163
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma.
Yang F; Jiang M; Lu M; Hu P; Wang H; Jiang J
Front Pharmacol; 2018; 9():991. PubMed ID: 30210349
[No Abstract] [Full Text] [Related]
8. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
Krishna R; Webb MS; St Onge G; Mayer LD
J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
[TBL] [Abstract][Full Text] [Related]
9. Determination of free and total vincristine in human plasma after intravenous administration of vincristine sulfate liposome injection using ultra-high performance liquid chromatography tandem mass spectrometry.
Yang F; Wang H; Liu M; Hu P; Jiang J
J Chromatogr A; 2013 Feb; 1275():61-9. PubMed ID: 23294995
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of liposomal vincristine.
Gelmon KA; Tolcher A; Diab AR; Bally MB; Embree L; Hudon N; Dedhar C; Ayers D; Eisen A; Melosky B; Burge C; Logan P; Mayer LD
J Clin Oncol; 1999 Feb; 17(2):697-705. PubMed ID: 10080616
[TBL] [Abstract][Full Text] [Related]
11. Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias.
Shah NN; Merchant MS; Cole DE; Jayaprakash N; Bernstein D; Delbrook C; Richards K; Widemann BC; Wayne AS
Pediatr Blood Cancer; 2016 Jun; 63(6):997-1005. PubMed ID: 26891067
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.
Bedikian AY; Silverman JA; Papadopoulos NE; Kim KB; Hagey AE; Vardeleon A; Hwu WJ; Homsi J; Davies M; Hwu P
J Clin Pharmacol; 2011 Aug; 51(8):1205-12. PubMed ID: 20978276
[TBL] [Abstract][Full Text] [Related]
13. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.
Silverman JA; Deitcher SR
Cancer Chemother Pharmacol; 2013 Mar; 71(3):555-64. PubMed ID: 23212117
[TBL] [Abstract][Full Text] [Related]
14. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
[TBL] [Abstract][Full Text] [Related]
15. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity.
Deitcher OR; Glaspy J; Gonzalez R; Sato T; Bedikian AY; Segarini K; Silverman J; Deitcher SR
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):197-202. PubMed ID: 24417913
[TBL] [Abstract][Full Text] [Related]
16. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents.
Frost BM; Lönnerholm G; Koopmans P; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Uges DR; de Graaf SS
Acta Paediatr; 2003 May; 92(5):551-7. PubMed ID: 12839283
[TBL] [Abstract][Full Text] [Related]
17. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D; Heffner LT; Larson M; Seiter K; Smith S; Assouline S; Kuriakose P; Maness L; Nagler A; Rowe J; Schaich M; Shpilberg O; Yee K; Schmieder G; Silverman JA; Thomas D; Deitcher SR; Kantarjian H
J Clin Oncol; 2013 Feb; 31(6):676-83. PubMed ID: 23169518
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of liposomal-encapsulated and un-encapsulated vincristine after injection of liposomal vincristine sulfate in beagle dogs.
Zhong J; Mao W; Shi R; Jiang P; Wang Q; Zhu R; Wang T; Ma Y
Cancer Chemother Pharmacol; 2014 Mar; 73(3):459-66. PubMed ID: 24362508
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
20. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]